827 related articles for article (PubMed ID: 24738694)
1. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
2. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
3. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
Cicero TJ; Ellis MS; Kasper ZA
Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
[TBL] [Abstract][Full Text] [Related]
4. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
[TBL] [Abstract][Full Text] [Related]
5. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
[TBL] [Abstract][Full Text] [Related]
8. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
Rauck RL
Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
[TBL] [Abstract][Full Text] [Related]
9. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
[TBL] [Abstract][Full Text] [Related]
10. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
[TBL] [Abstract][Full Text] [Related]
11. A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population.
Jewell J; Black J; Ellis M; Olsen H; Iwanicki J; Dart R
Clin Drug Investig; 2023 Mar; 43(3):197-203. PubMed ID: 36859697
[TBL] [Abstract][Full Text] [Related]
12. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
[TBL] [Abstract][Full Text] [Related]
13. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
Cheng HG; Coplan PM
Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
[TBL] [Abstract][Full Text] [Related]
14. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
15. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
[TBL] [Abstract][Full Text] [Related]
17. The implications of tamper-resistant formulations for opioid rotation.
Pappagallo M; Sokolowska M
Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
[TBL] [Abstract][Full Text] [Related]
18. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
[TBL] [Abstract][Full Text] [Related]
19. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484
[TBL] [Abstract][Full Text] [Related]
20. Oxycodone extended release capsules for the treatment of chronic pain.
Mercadante S
Expert Rev Neurother; 2017 May; 17(5):427-431. PubMed ID: 28277802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]